Hexaell Biotech

Hexaell Biotech is a groundbreaking startup focused on advancing stem cell and artificial organ technology, with a particular emphasis on innovative solutions for liver failure treatment. Leveraging pioneering research from the Chinese Academy of Sciences, which has been prominently featured in prestigious publications like Nature and Cell Stem Cell, the company has established itself as a trailblazer in the field. With the rights to iHep and HiHep technologies, Hexaell Biotechnology has developed bio-artificial liver medical devices designed to emulate liver function and address liver failure diseases. The company's efforts have culminated in the successful completion of pilot clinical studies involving six liver failure patients at leading hepatopathy centers in China. Founded in 2015, Hexaell Biotechnology operates within the Biotechnology and Health Care industries, aiming to drive meaningful advancements in medical technology. Its most recent milestone is a $7.27M Series A investment secured on 25 December 2018, with funding coming from prominent investors including Hyfinity Investments, Sherpa Healthcare Partners, and Breakthrough Capital. This injection of capital is poised to further propel the development and deployment of the company's pioneering solutions, solidifying its position at the forefront of innovation in the medical technology landscape.